TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

1,1318

13-марта-25 13:34:44

15 мин. задержка

Акции

+0,0218

+1,96%

Сегодняшний диапазон

1,0800 - 1,2050

ISIN

N/A

Источник

NASDAQ

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

05 дек 2024 11:03:20 Источник Nasdaq GlobeNewswire
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy

26 ноя 2024 08:05:00 Источник Nasdaq GlobeNewswire
Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

21 ноя 2024 15:59:43 Источник Nasdaq GlobeNewswire
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

19 ноя 2024 16:50:42 Источник Nasdaq GlobeNewswire
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

14 ноя 2024 17:00:38 Источник Nasdaq GlobeNewswire
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

14 ноя 2024 15:49:39 Источник Nasdaq GlobeNewswire
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

08 ноя 2024 15:36:48 Источник Nasdaq GlobeNewswire
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability

05 ноя 2024 16:43:31 Источник Nasdaq GlobeNewswire
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

05 ноя 2024 09:27:48 Источник Nasdaq GlobeNewswire
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

04 ноя 2024 14:36:34 Источник Nasdaq GlobeNewswire
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

31 окт 2024 10:54:56 Источник Nasdaq GlobeNewswire
Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

29 окт 2024 15:28:32 Источник Nasdaq GlobeNewswire
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

29 окт 2024 12:43:30 Источник Nasdaq GlobeNewswire
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

25 окт 2024 17:34:17 Источник Nasdaq GlobeNewswire
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

23 окт 2024 08:35:00 Источник Nasdaq GlobeNewswire
Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week

22 окт 2024 14:30:00 Источник Nasdaq GlobeNewswire
Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

21 окт 2024 15:58:22 Источник Nasdaq GlobeNewswire
Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

21 окт 2024 13:56:12 Источник Nasdaq GlobeNewswire
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

18 окт 2024 22:46:52 Источник Nasdaq GlobeNewswire
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

17 окт 2024 09:32:57 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.